Eugene Athan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2317100/publications.pdf

Version: 2024-02-01

101543 74163 6,061 110 36 75 citations h-index g-index papers 114 114 114 6493 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pediatric <i>Staphylococcus aureus</i> Bacteremia: Clinical Spectrum and Predictors of Poor Outcome. Clinical Infectious Diseases, 2022, 74, 604-613.	5.8	13
2	Whole genome sequencing and molecular epidemiology of paediatric Staphylococcus aureus bacteraemia. Journal of Global Antimicrobial Resistance, 2022, 29, 197-206.	2.2	6
3	Early SARSâ€CoVâ€2â€associated acute transverse myelitis: A case for neurotropism?. Journal of Internal Medicine, 2022, 292, 679-683.	6.0	4
4	Preventing the development of severe COVID-19 by modifying immunothrombosis. Life Sciences, 2021, 264, 118617.	4.3	40
5	C-reactive protein predicts complications in community-associated S. aureus bacteraemia: a cohort study. BMC Infectious Diseases, 2021, 21, 312.	2.9	2
6	Infective Endocarditis in Patients on Chronic Hemodialysis. Journal of the American College of Cardiology, 2021, 77, 1629-1640.	2.8	23
7	Pregnancy – a key moment for engaging women with hepatitis B in care. Australian and New Zealand Journal of Public Health, 2021, 45, 299-300.	1.8	3
8	The impact of infectious diseases consultation on the management and outcomes of Pseudomonas aeruginosa bacteraemia in adults: a retrospective cohort study. BMC Infectious Diseases, 2021, 21, 671.	2.9	9
9	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. Cytokine, 2021, 144, 155593.	3.2	61
10	Psychiatrists can treat hepatitis C. Journal of Viral Hepatitis, 2021, 28, 1763-1764.	2.0	1
11	Barriers to performing onsite COVID-19 testing during the second wave in Victoria: Experiences of general practices. Australian Journal of General Practice, 2021, 50, 845-849.	0.8	1
12	FMT for psychiatric disorders: Following the brown brick road into the future. Bipolar Disorders, 2021, 23, 651-655.	1.9	8
13	Correlation between Buruli Ulcer Incidence and Vectorborne Diseases, Southeastern Australia, 2000–2020. Emerging Infectious Diseases, 2021, 27, 3191-3192.	4.3	3
14	Enterococcal bacteraemia †silent but deadly': a populationâ€based cohort study. Internal Medicine Journal, 2020, 50, 434-440.	0.8	13
15	Six vs Eight Weeks of Antibiotics for Small Mycobacterium ulcerans Lesions in Australian Patients. Clinical Infectious Diseases, 2020, 70, 1993-1997.	5.8	7
16	Cost and Outcomes of Implantable Cardiac Electronic Device Infections in Victoria, Australia. Heart Lung and Circulation, 2020, 29, e140-e146.	0.4	5
17	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. Life Sciences, 2020, 262, 118541.	4.3	12
18	The effectiveness of a simple antimicrobial stewardship intervention in general practice in Australia: a pilot study. BMC Infectious Diseases, 2020, 20, 586.	2.9	4

#	Article	IF	CITATIONS
19	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. Life Sciences, 2020, 258, 118166.	4.3	79
20	Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than <i>Clostridium difficile</i> infection: a systematic review and meta-analysis. Gut Microbes, 2020, 12, 1854640.	9.8	81
21	In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection. Drugs in R and D, 2020, 20, 209-216.	2.2	10
22	Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	3
23	Cell-mediated and serology-based tests for Mycobacterium ulcerans disease: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2020, 14, e0008172.	3.0	2
24	Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1231-1238.	3.6	36
25	Antimicrobial anaphylaxis: the changing face of severe antimicrobial allergy. Journal of Antimicrobial Chemotherapy, 2019, 75, 229-235.	3.0	7
26	Central venous catheter associated blood stream infections (CVC-BSIs) in the non-intensive care settings: Epidemiology, microbiology and outcomes. Infection, Disease and Health, 2019, 24, 222-228.	1.1	9
27	Faecal microbiota transplants for depression – Who gives a crapsule?. Australian and New Zealand Journal of Psychiatry, 2019, 53, 732-734.	2.3	13
28	Spontaneous healing of Mycobacterium ulcerans disease in Australian patients. PLoS Neglected Tropical Diseases, 2019, 13, e0007178.	3.0	22
29	Critical care burden of skin and soft tissue infection in Central Australia: More than skin deep. Australian Journal of Rural Health, 2019, 27, 550-556.	1.5	7
30	Association between the timing of surgery for complicated, left-sided infective endocarditis and survival. American Heart Journal, 2019, 210, 108-116.	2.7	24
31	The changing epidemiology worldwide of <i>Mycobacterium ulcerans </i> . Epidemiology and Infection, 2019, 147, e19.	2.1	36
32	<i>Mycobacterium ulcerans</i> disease management in Australian patients: the reâ€emergence of surgery as an important treatment modality. ANZ Journal of Surgery, 2019, 89, 653-658.	0.7	11
33	Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe directâ€acting antiviral therapy for hepatitis C. Journal of Viral Hepatitis, 2018, 25, 1089-1098.	2.0	26
34	Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia. BMC Infectious Diseases, 2018, 18, 107.	2.9	26
35	Fosfomycin: what was old is new again. Internal Medicine Journal, 2018, 48, 1425-1429.	0.8	5
36	Low incidence of recurrent Buruli ulcers in treated Australian patients living in an endemic region. PLoS Neglected Tropical Diseases, 2018, 12, e0006724.	3.0	4

#	Article	IF	CITATIONS
37	Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response. Medical Journal of Australia, 2018, 208, 287-289.	1.7	22
38	Increased Severity and Spread of <i>Mycobacterium ulcerans </i> , Southeastern Australia. Emerging Infectious Diseases, 2018, 24, 58-64.	4.3	48
39	Wound healing: Natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease. PLoS Neglected Tropical Diseases, 2018, 12, e0006357.	3.0	16
40	Antibiotic complications during the treatment of <i>Mycobacterium ulcerans</i> disease in Australian patients. Internal Medicine Journal, 2017, 47, 1011-1019.	0.8	20
41	Identifying and integrating patient and caregiver perspectives for clinical practice guidelines on the screening and management of infectious microorganisms in hemodialysis units. Hemodialysis International, 2017, 21, 213-223.	0.9	13
42	Exposure Risk for Infection and Lack of Human-to-Human Transmission of <i>Mycobacterium ulcerans </i> li>Disease, Australia. Emerging Infectious Diseases, 2017, 23, 837-840.	4.3	24
43	Validated Risk Score for Predicting 6â€Month Mortality in Infective Endocarditis. Journal of the American Heart Association, 2016, 5, e003016.	3.7	98
44	Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. Antimicrobial Agents and Chemotherapy, 2016, 60, 2692-2695.	3.2	33
45	Australasian Society of Infectious Diseases updated guidelines for the management of <i>Clostridium difficile</i> infection in adults and children in Australia and New Zealand. Internal Medicine Journal, 2016, 46, 479-493.	0.8	88
46	Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. New England Journal of Medicine, 2016, 375, 1019-1032.	27.0	752
47	Evolving epidemiology of injecting drug use-associated infective endocarditis: A regional centre experience. Drug and Alcohol Review, 2015, 34, 412-417.	2.1	30
48	Mycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal Outcomes. PLoS Neglected Tropical Diseases, 2015, 9, e0004253.	3.0	19
49	Candida Infective Endocarditis: an Observational Cohort Study with a Focus on Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 2365-2373.	3.2	68
50	Sequence type 131 fimH30 and fimH41 subclones amongst Escherichia coli isolates in Australia and New Zealand. International Journal of Antimicrobial Agents, 2015, 45, 351-358.	2.5	18
51	Mycobacterium Ulcerans Treatment – Can Antibiotic Duration Be Reduced in Selected Patients?. PLoS Neglected Tropical Diseases, 2015, 9, e0003503.	3.0	21
52	Clinical MRSA isolates from skin and soft tissue infections show increased inÂvitro production of phenol soluble modulins. Journal of Infection, 2015, 71, 447-457.	3.3	28
53	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24.	1.6	57
54	Survey of infection control and antimicrobial stewardship practices in ⟨scp⟩A⟨/scp⟩ustralian residential agedâ€care facilities. Internal Medicine Journal, 2015, 45, 576-580.	0.8	15

#	Article	IF	CITATIONS
55	Association Between Surgical Indications, Operative Risk, and Clinical Outcome in Infective Endocarditis. Circulation, 2015, 131, 131-140.	1.6	211
56	Impact of Early Valve Surgery on Outcome of Staphylococcus aureus Prosthetic Valve Infective Endocarditis: Analysis in the International Collaboration of Endocarditis–Prospective Cohort Study. Clinical Infectious Diseases, 2015, 60, 741-749.	5.8	84
57	Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Medical Journal of Australia, 2014, 200, 267-270.	1.7	60
58	Transmission of tuberculosis infection in a commercial office. Medical Journal of Australia, 2014, 200, 177-179.	1.7	4
59	Clinical Features and Risk Factors of Oedematous Mycobacterium ulcerans Lesions in an Australian Population: Beware Cellulitis in an Endemic Area. PLoS Neglected Tropical Diseases, 2014, 8, e2612.	3.0	19
60	latrogenic Meningitis Caused by <i>Neisseria sicca/subflava </i> latrogenic Meningitis Caused by <i>Neisseria sicca/subflava </i> latrogenic Intrathecal Contrast Injection, Australia. Emerging Infectious Diseases, 2014, 20, 1023-1025.	4.3	8
61	The Characteristics and Outcome of Infective Endocarditis Involving Implantable Cardiac Devices. Current Infectious Disease Reports, 2014, 16, 446.	3.0	5
62	Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. Internal Medicine Journal, 2014, 44, 1389-1397.	0.8	30
63	Community-Onset Escherichia coli Infection Resistant to Expanded-Spectrum Cephalosporins in Low-Prevalence Countries. Antimicrobial Agents and Chemotherapy, 2014, 58, 2126-2134.	3.2	33
64	Staphylococcus aureus bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1003-1008.	2.9	48
65	Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clinical Microbiology and Infection, 2013, 19, 1140-1147.	6.0	120
66	Compliance with surgical antibiotic prophylaxis at an Australian teaching hospital. American Journal of Infection Control, 2013, 41, 71-74.	2.3	27
67	Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulceransinfections. BMC Infectious Diseases, 2013, 13, 416.	2.9	50
68	Early diagnosis and treatment of necrotizing fasciitis can improve survival: an observational intensive care unit cohort study. ANZ Journal of Surgery, 2013, 83, 365-370.	0.7	50
69	The effectiveness of a single-stage versus traditional three-staged protocol of hospital disinfection at eradicating vancomycin-resistant Enterococci from frequently touched surfaces. American Journal of Infection Control, 2013, 41, 227-231.	2.3	12
70	Outpatient parenteral antimicrobial therapy is safe and effective for the treatment of infective endocarditis: a retrospective cohort study. Internal Medicine Journal, 2013, 43, 700-705.	0.8	25
71	Forgotten but not gone - Scrofuloderma in a migrant student from India. Australasian Medical Journal, 2013, 6, 371-373.	0.1	1
72	Mycobacterium ulcerans Disease: Experience with Primary Oral Medical Therapy in an Australian Cohort. PLoS Neglected Tropical Diseases, 2013, 7, e2315.	3.0	35

#	Article	IF	Citations
73	A case of Kingella kingae endocarditis complicated by native mitral valve. Australasian Medical Journal, 2013, 6, 172-174.	0.1	3
74	Updated Creutzfeldt–Jakob disease infection control guidelines: sifting facts from fiction. Medical Journal of Australia, 2013, 198, 245-246.	1.7	2
75	Risk factors for recurrent Mycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort. Medical Journal of Australia, 2013, 198, 436-439.	1.7	26
76	Impact of Hiv-Associated Conditions on Mortality in People Commencing Anti-Retroviral Therapy in Resource Limited Settings. PLoS ONE, 2013, 8, e68445.	2.5	21
77	Updated Creutzfeldt–Jakob disease infection control guidelines: sifting facts from fiction. Medical Journal of Australia, 2013, 199, 535-536.	1.7	1
78	Successful Outcomes with Oral Fluoroquinolones Combined with Rifampicin in the Treatment of Mycobacterium ulcerans: An Observational Cohort Study. PLoS Neglected Tropical Diseases, 2012, 6, e1473.	3.0	56
79	Clinical Characteristics and Outcome of Infective Endocarditis Involving Implantable Cardiac Devices. JAMA - Journal of the American Medical Association, 2012, 307, 1727.	7.4	247
80	Treatment costs of Mycobacterium ulcerans in the antibiotic era. International Health, 2012, 4, 123-127.	2.0	24
81	Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. Medical Journal of Australia, 2012, 196, 341-344.	1.7	68
82	Spontaneous bacterial peritonitis: a rare mimic of acute appendicitis. ANZ Journal of Surgery, 2012, 82, 283-284.	0.7	6
83	Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings. Aids, 2010, 24, 1887-1895.	2.2	11
84	Management of Potential Laboratory Exposure to Avian Influenza (H5N1) Virus Implications for Pandemic Planning. Infection Control and Hospital Epidemiology, 2009, 30, 504-506.	1.8	0
85	Candida infective endocarditis. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 519-529.	2.9	188
86	Preventing invasive fungal infection during hospital building works. Internal Medicine Journal, 2008, 38, 538-541.	0.8	26
87	Successful control of an outbreak of invasive aspergillosis in a regional haematology unit during hospital construction works. Journal of Hospital Infection, 2008, 69, 33-38.	2.9	28
88	Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report. Journal of Medical Case Reports, 2008, 2, 123.	0.8	16
89	Genotypic Diversity of Coagulase-Negative Staphylococci Causing Endocarditis: a Global Perspective. Journal of Clinical Microbiology, 2008, 46, 1780-1784.	3.9	40
90	Emergence of Coagulase-Negative Staphylococci as a Cause of Native Valve Endocarditis. Clinical Infectious Diseases, 2008, 46, 232-242.	5 . 8	160

#	Article	IF	CITATIONS
91	Contemporary Clinical Profile and Outcome of Prosthetic Valve Endocarditis. JAMA - Journal of the American Medical Association, 2007, 297, 1354.	7.4	550
92	Incidence of Catheter-Related Bloodstream Infection Among Patients With a Needleless, Mechanical Valve–Based Intravenous Connector in an Australian Hematology-Oncology Unit. Infection Control and Hospital Epidemiology, 2007, 28, 610-613.	1.8	79
93	Pacemaker Infections: A 10-Year Experience. Heart Lung and Circulation, 2007, 16, 434-439.	0.4	79
94	Teicoplanin hypersensitivity syndrome. International Journal of Antimicrobial Agents, 2007, 29, 476-478.	2.5	9
95	Personal Protective Equipment and Antiviral Drug Use during Hospitalization for Suspected Avian or Pandemic Influenza ¹	4.3	44
96	Risk Factors for <i>Mycobacterium ulcerans </i> Infection, Southeastern Australia. Emerging Infectious Diseases, 2007, 13, 1661-1666.	4.3	101
97	Mycobacterium ulcerans infection: factors influencing diagnostic delay. Medical Journal of Australia, 2007, 187, 561-563.	1.7	37
98	Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a southâ€eastern Australian case series. Medical Journal of Australia, 2007, 186, 58-61.	1.7	62
99	Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Medical Journal of Australia, 2007, 186, 64-68.	1.7	93
100	Postoperative enteritis due to methicillin-resistant Staphylococcus aureus. ANZ Journal of Surgery, 2006, 76, 763-763.	0.7	2
101	Prevalence of multiresistant Gram-negative organisms in a surgical hospital in Ho Chi Minh Cit, Vietnam. Tropical Medicine and International Health, 2006, 11, 1725-1730.	2.3	10
102	Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 753-755.	2.9	65
103	Peritonitis Due to Curvularia inaequalis in an Elderly Patient Undergoing Peritoneal Dialysis and a Review of Six Cases of Peritonitis Associated with Other Curvularia spp. Journal of Clinical Microbiology, 2005, 43, 4288-4292.	3.9	32
104	Staphylococcus aureus Endocarditis. JAMA - Journal of the American Medical Association, 2005, 293, 3012.	7.4	990
105	Control of an outbreak of multi-drug-resistant Acinetobacter baumannii in an intensive care unit and a surgical ward. Journal of Hospital Infection, 2005, 59, 249-253.	2.9	45
106	Serotonin syndrome due to co-administration of linezolid and venlafaxine. Journal of Antimicrobial Chemotherapy, 2004, 54, 289-290.	3.0	46
107	Prevention of recurrent fetal death in utero due to group B streptococcal chorioamnionitis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2004, 44, 356-357.	1.0	1
108	AIDS and heart disease: Is cardiac surgery justified?. Heart Lung and Circulation, 2003, 12, 193-195.	0.4	1

#	Article	lF	CITATIONS
109	The changing profile of bacterial endocarditis as seen at an australian provincial centre. Heart Lung and Circulation, 2002, 11, 26-31.	0.4	13
110	Onceâ€Daily Intravenous Cefazolin Plus Oral Probenecid Is Equivalent to Onceâ€Daily Intravenous Ceftriaxone Plus Oral Placebo for the Treatment of Moderateâ€toâ€Severe Cellulitis in Adults. Clinical Infectious Diseases, 2002, 34, 1440-1448.	5.8	70